Loading...
Vorinostat plus tacrolimus/methotrexate to prevent GVHD after myeloablative conditioning, unrelated donor HCT
The oral histone deacetylase (HDAC) inhibitor (vorinostat) is safe and results in low incidence of acute graft-versus-host disease (GVHD) after reduced-intensity conditioning, related donor hematopoietic cell transplantation (HCT). However, its safety and efficacy in preventing acute GVHD in setting...
Saved in:
Published in: | Blood |
---|---|
Main Authors: | , , , , , , , , , , |
Format: | Artigo |
Language: | Inglês |
Published: |
American Society of Hematology
2017
|
Subjects: | |
Online Access: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5639486/ https://ncbi.nlm.nih.gov/pubmed/28784598 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2017-06-790469 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|